The company maintained its 2025 guidance, with revenue projected at $4.15-$4.35 billion, flat at the midpoint year-over-year. Adjusted EBITDA remains at $870-$950 million, up 1% at the midpoint (4% excluding the GSS divestiture). The outlook includes $15-$20 million in added tariff costs. Adjusted EPS is unchanged at $3.26-$3.70, flat at the midpoint, and free cash flow is still expected between $200 million and $400 million. Key Takeaways FMC Corporation (FMC) introduced its novel fluindapyr technology upo ...